Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOS1 | P29475 | 5/20 | 0.39 |
| ▸ | MEN1 | O00255 | 2/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.34 |
| ▸ | ADRB3 | P13945 | 2/20 | 0.33 |
| ▸ | LRRK2 | Q5S007 | 1/20 | 0.33 |
| ▸ | MGLL | Q99685 | 1/20 | 0.32 |
| ▸ | ELANE | P08246 | 1/20 | 0.32 |
| ▸ | NOS3 | P29474 | 1/20 | 0.31 |
| ▸ | LMNA | P02545 | 1/20 | 0.31 |
| ▸ | HTT | P42858 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | FDPS | P14324 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27710074 | 0.83 | MEN1 (0.35) | NOS1MEN1KMT2AADRB3MGLL | |
| SCHEMBL3091768 | 0.82 | ALDH1A1 (0.43) | NOS1MEN1KMT2AADRB3ELANE | |
| SCHEMBL6434486 | 0.82 | MEN1 (0.37) | NOS1MEN1KMT2AADRB3MGLL | |
| SCHEMBL31354980 | 0.82 | ALDH1A1 (0.43) | NOS1MEN1KMT2AADRB3ELANE | |
| SCHEMBL4663219 | 0.82 | ALDH1A1 (0.43) | NOS1MEN1KMT2AADRB3ELANE | |
| SCHEMBL30697576 | 0.77 | KMT2A (0.38) | MEN1KMT2AADRB3ALDH1A1 | |
| SCHEMBL19292029 | 0.77 | ADRB3 (0.41) | NOS1MEN1KMT2AADRB3ELANE | |
| SCHEMBL10362298 | 0.77 | KMT2A (0.38) | MEN1KMT2AADRB3ALDH1A1 | |
| SCHEMBL10513126 | 0.77 | FDPS (0.36) | NOS1MEN1KMT2AADRB3HTT | |
| SCHEMBL3752518 | 0.76 | NOS1 (0.36) | NOS1FDPS |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-119306664-A | Novel heterocyclic compounds as Pol theta inhibitors for the treatment and prevention of cancer and pharmaceutical compositions containing the same | 株式会社大熊制药 | 2025-01-14 | — | — | CN | claimed |
| CN-119306664-A | Novel heterocyclic compounds as Pol theta inhibitors for the treatment and prevention of cancer and pharmaceutical compositions containing the same | 株式会社大熊制药 | 2025-01-14 | — | — | CN | disclosed |
| US-20240124439-A1 | Pyrido[2,3-D]Imidazole Derivatives and Their Use As Inhibitors of ITK for the Treatment of Skin Disease | PFIZER INC. (US) | 2024-04-18 | — | — | US | disclosed |
| CN-115701991-A | Pyrazolylpropionamide compounds and their use for treating prostate cancer | 田纳西大学研究基金会 | 2023-02-14 | — | — | CN | disclosed |
| EP-4125846-A1 | PYRAZOLYLPROPANAMIDE COMPOUNDS AND USES THEREOF FOR TREATMENT OF PROSTATE CANCER | University of Tennessee Research Foundation (US) | 2023-02-08 | — | — | EP | disclosed |
| WO-2021257857-A1 | NAPHTHYRIDINONE COMPOUNDS AS JAK2 V617F INHIBITORS | INCYTE CORPORATION (US) | 2021-12-23 | — | — | WO | disclosed |
| WO-2021202936-A1 | PYRAZOLYLPROPANAMIDE COMPOUNDS AND USES THEREOF FOR TREATMENT OF PROSTATE CANCER | UNIVERSITY OF TENNESSEE RESEARCH FOUNDATION (US) | 2021-10-07 | — | — | WO | disclosed |
| CN-102993195-B | Substitutional-2-(chroman-6-oxyl) thiazole and application thereof as medicine | 赛诺菲 | 2017-05-17 | — | — | CN | disclosed |
| EP-2763990-A1 | PYRROLOPYRAZINE KINASE INHIBITORS | F.HOFFMANN-LA ROCHE AG (CH) | 2014-08-13 | — | — | EP | disclosed |
| WO-2014067985-A1 | COMPOUNDS FOR USE IN THE TREATMENT OF PARASITIC DISEASES | IRBM SCIENCE PARK S.P.A. (IT) | 2014-05-08 | — | — | WO | disclosed |
| CN-102993195-A | Substitutional-2-(chroman-6-oxyl) thiazole and application thereof as medicine | SAI NUOFEI | 2013-03-27 | — | — | CN | disclosed |
| WO-2013030138-A1 | PYRROLOPYRAZINE KINASE INHIBITORS | F. HOFFMANN-LA ROCHE AG (CH) | 2013-03-07 | — | — | WO | disclosed |
| CN-1070641-A | Quinoxalinyl oxygen ether with the mutual resistance weeding of relevant application | DU PONT (US) | 1993-04-07 | — | — | CN | disclosed |
| CN-1069271-A | Preparation [1] chromene is the method for [4,3-c] pyrazole compound also | BOOTS CO PLC (GB) | 1993-02-24 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240124439-A1 | Pyrido[2,3-D]Imidazole Derivatives and Their Use As Inhibitors of ITK for the Treatment of Skin Disease | ITK, PDXK, HRH4 | NOS1 855/4885MEN1 3769/4885KMT2A 2407/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.